Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ME2 | P23368 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374613 | 1.00 | HDAC1 (1.00) | HDAC1MAPTKMT2AMEN1LMNA | |
| SCHEMBL4121311 | 1.00 | HDAC1 (1.00) | HDAC1MAPTKMT2AMEN1LMNA | |
| SCHEMBL4125967 | 0.99 | HDAC1 (0.97) | HDAC1MAPTKMT2AMEN1LMNA | |
| SCHEMBL4124097 | 0.96 | HDAC1 (0.92) | HDAC1MAPTKMT2AMEN1LMNA | |
| SCHEMBL3999754 | 0.91 | HDAC1 (0.82) | HDAC1MAPTKMT2AMEN1LMNA | |
| SCHEMBL12150976 | 0.87 | HDAC1 (0.77) | HDAC1MAPTLMNANPSR1HTR7 | |
| SCHEMBL14159458 | 0.87 | HDAC1 (0.77) | HDAC1MAPTLMNANPSR1HTR7 | |
| SCHEMBL1377912 | 0.87 | HDAC1 (0.77) | HDAC1MAPTLMNANPSR1HDAC8 | |
| SCHEMBL1374177 | 0.86 | MAPT (0.78) | HDAC1MAPTKMT2AMEN1LMNA | |
| SCHEMBL1374706 | 0.86 | MAPT (0.78) | HDAC1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694329-A4 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES | ATON PHARMA INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1694329-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES | Aton Pharma, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005053610-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | AADAC, BRDT, HDAC5 | HDAC1 5/4885MAPT 1274/4885KMT2A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.